Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
When introduced simultaneously, they prevent early receptor satiety and produce a more pronounced pulsatile release than either peptide used in isolation
Key Research Highlights Studied for its involvement in IGF-1 signalling pathways Frequently referenced in cell growth and metabolic research models Research interest in tissue response and recovery pathways Modified peptide analogue designed for enhanced research stability Supplied in sterile vials to support consistent laboratory handling Available Dosage Options Select your vial strength from the dropdown menu: IGF-1 LR3 0.1mg (100mcg) IGF-1 LR3 1mg (1000mcg) Product Information Peptide: IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) Form: Lyophilised powder Vial Type: Sterile sealed research vial Strength Options: 0.1mg / 1mg Use: Research / laboratory use only Not for human consumption Storage Guidelines For best stability: Store unreconstituted vials refrigerated in a dry environment After reconstitution, store at 28C Protect from direct light and heat Use sterile technique when handling to reduce contamination risk Important Research Notice This product is sold strictly for research purposes only
Nausea, vomiting, and delayed gastric emptying caused by tirzepatide result from GLP-1 receptor activation in the gut and hypothalamus, not from oxidative stress
Journal of Alternative and Complementary Medicine
The lipotropic compounds in the injection help break down fat more efficiently, potentially aiding in weight loss efforts
Standard recovery 4 to 8 weeks
